Figure S1. STR analysis of HepG2 cells. Genomic DNA was extracted and PCR was performed to amplify the STR locus. STR analysis was performed using Genemapper 5 by Bionics Co., Ltd. HepG2 was matched to HB-8065, CRL-11997, MRA-975 and CRL-10741.

HepG2

STR analysis result

| Marker | Allele 1 | Allele 2 | Peak 1 | Allele 1-ht | Peak 2 | Allele 2-ht |
|---------|----------|----------|--------|-------------|--------|-------------|
| AMEL | х | Y | 107.67 | 1564 | 113.11 | 1623 |
| CSF1PO | 10 | 11 | 320.31 | 1026 | 324.33 | 878 |
| D13S317 | 9 | 13 | 222.04 | 2742 | 237.88 | 2931 |
| D16S539 | 12 | 13 | 280.77 | 5074 | 284.7 | 2441 |
| D18S51 | 13 | 14 | 288.9 | 2223 | 293.01 | 1843 |
| D19S433 | 15.2 | | 127.53 | 3435 | | |
| D21S11 | 29 | 31 | 205.03 | 604 | 212.97 | 724 |
| D2S1338 | 19 | 20 | 323.8 | 1884 | 327.99 | 4144 |
| D3S1358 | 15 | 16 | 125.26 | 2338 | 129.33 | 2439 |
| D5S818 | 11 | 12 | 152.37 | 1207 | 156.46 | 1367 |
| D7S820 | 10 | | 272.27 | 1231 | | |
| D8S1179 | 15 | 16 | 154.98 | 1014 | 159.01 | 1262 |
| FGA | 22 | 25 | 237.26 | 1382 | 249.56 | 1232 |
| TH01 | 9 | | 184.02 | 6880 | | |
| трох | 8 | 9 | 230.93 | 2271 | 234.89 | 5435 |
| vWA | 17 | | 179.41 | 4684 | | |

CLA analysis result

| 0/ Matala | 100.0 | 100.0 | 100.0 | 02.0 |
|-------------|--|---------------------------|---------|---|
| % Match | 100.0 | 100.0 | 100.0 | 93.0 |
| Atcc Number | HB-8065 | CRL-11997 | MRA-975 | CRL-10741 |
| Designation | Hep G2 Hepatocellular Carcinoma Human | HEP G2/2.2.1 CELL LINE | HC-04 | C3A (HepG2/C3A) Hepatocellular CarcinomaHuman |
| D5S818 | 11,12 | 11,12 | 11,12 | 11,13 |
| D13S317 | 9,13 | 9,13 | 9,13 | 9,13 |
| D7S820 | 10 | 10 | 10 | 10 |
| D16S539 | 12,13 | 12,13 | 12 | 12,13 |
| vWA | 17 | 17 | 17 | 17 |
| TH01 | 9 | 9 | 9 | 9 |
| AMEL | X,Y | X,Y | X,Y | X,Y |
| TPOX | 8,9 | 8,9 | 8,9 | 8,9 |
| CSF1PO | 10,11 | 10,11 | 10,11 | 10,11 |

Figure S2. Exosomes from T-MSCs were detected by Nanosight particle tracking analysis. Left, T-MSCs of different origins; right, overall size of the exosomes isolated from T-MSCs of different origins. T-MSC, tonsil-derived mesenchymal stem cell.






Figure S3. Characterization of T-MSCs. (A) Surface markers of T-MSCs of different origins were analyzed by flow cytometry. (B) Adipogenic differentiation of T-MSCs of different origins. The lipid droplets were visualized red under phase contrast microscope. T-MSC, tonsil-derived mesenchymal stem cell.





Original magnification ×400

Figure S4. miRNA sequencing comparison of T-CM and DMEM. (A) Heat map of one-way hierarchical clustering. (B) Significant mature miRNA count by fold change. n=5 in CM group; n=1 in DMEM group. miRNAs exhibiting log₂FC>2 were considered to be differentially expressed. (C) Hierarchical clustering analysis. Using each sample's normalized value, the high expression similarities were grouped together. Distance metric=Euclidean distance; linkage method=complete linkage. T-CM, tonsil-derived mesenchymal stem cell conditioned medium; miRNA, microRNA; DMEM-C, DMEM-only negative control.




Figure S5. miRNA pathway analysis. The top 20 miRNAs identified in tonsil-derived mesenchymal stem cell exosomes were subjected to analysis using mirDIP, an integrative database of human miRNA target predictions, to determine whole miRNA target genes with high confidence. A total of 3,393 genes derived from mirDIP were further analyzed by Database for Annotation, Visualization and Integrated Discovery v6.8 to identify enriched biological pathways. miRNA, microRNA.




Figure S6. Transfection efficiency of miR-199a-3p inhibitor. The expression of hsa-miR-199a-3p and RNU6-1 in HepG2 cells transfected with negative control of miRNA inhibitor or has-miR-199a-3p inhibitor was compared by reverse transcription-quantitative PCR in normal (purple) and HepG2 cells transfected with control inhibitor (black) or miR199a-3p inhibitor (green). Relative expression was compared by one-way ANOVA with multiple comparison by Sidak test. Data are presented as the mean ± standard error of the mean. ****P<0.0001 vs. miR-199a-3p inhibitor). miR, microRNA; NL, normal HepG2 cells; CONT inhibitor, negative control of miRNA inhibitor; TF, transfectant.

